While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a ...
Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...
While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares ...
The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese ...
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved ...
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results